BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 32391193)

  • 1. Heterogeneity of immune microenvironment in ovarian cancer and its clinical significance: a retrospective study.
    Gao Y; Chen L; Cai G; Xiong X; Wu Y; Ma D; Li SC; Gao Q
    Oncoimmunology; 2020; 9(1):1760067. PubMed ID: 32391193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of immune microenvironment subtypes that predicted the prognosis of patients with ovarian cancer.
    Wang X; Li X; Wang X
    J Cell Mol Med; 2021 Apr; 25(8):4053-4061. PubMed ID: 33675171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and validation of pyroptosis-related gene landscape in prognosis and immunotherapy of ovarian cancer.
    Gao L; Ying F; Cai J; Peng M; Xiao M; Sun S; Zeng Y; Xiong Z; Cai L; Gao R; Wang Z
    J Ovarian Res; 2023 Jan; 16(1):27. PubMed ID: 36707884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive of N1-Methyladenosine Modifications Patterns and Immunological Characteristics in Ovarian Cancer.
    Liu J; Chen C; Wang Y; Qian C; Wei J; Xing Y; Bai J
    Front Immunol; 2021; 12():746647. PubMed ID: 34777359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of an Autophagy-Related Signature for Prognosis and Immunotherapy Response Prediction in Ovarian Cancer.
    Ding J; Wang C; Sun Y; Guo J; Liu S; Cheng Z
    Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between tumor mutation burden and immune infiltration in ovarian cancer.
    Fan S; Gao X; Qin Q; Li H; Yuan Z; Zhao S
    Int Immunopharmacol; 2020 Dec; 89(Pt A):107126. PubMed ID: 33189611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of three molecular subtypes based on immune infiltration in ovarian cancer and its prognostic value.
    Liu J; Tan Z; He J; Jin T; Han Y; Hu L; Song J; Huang S
    Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33043974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Notch-Related Gene Signature for Prognosis and Immune Response Prediction in Ovarian Cancer.
    Pi Y; Sun F; Zhang Z; Liu X; Lou G
    Medicina (Kaunas); 2023 Jul; 59(7):. PubMed ID: 37512088
    [No Abstract]   [Full Text] [Related]  

  • 9. Machine learning developed a CD8
    Chen R; Zheng Y; Fei C; Ye J; Fei H
    Sci Rep; 2024 Mar; 14(1):5794. PubMed ID: 38461331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycosylation-related genes mediated prognostic signature contribute to prognostic prediction and treatment options in ovarian cancer: based on bulk and single‑cell RNA sequencing data.
    You Y; Yang Q
    BMC Cancer; 2024 Feb; 24(1):207. PubMed ID: 38355446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction of an Immune Cell Infiltration Score to Evaluate the Prognosis and Therapeutic Efficacy of Ovarian Cancer Patients.
    Liu J; Wang Y; Yuan S; Wei J; Bai J
    Front Immunol; 2021; 12():751594. PubMed ID: 34745124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of copper metabolism-related subtypes and establishment of the prognostic model in ovarian cancer.
    Zhao S; Zhang X; Gao F; Chi H; Zhang J; Xia Z; Cheng C; Liu J
    Front Endocrinol (Lausanne); 2023; 14():1145797. PubMed ID: 36950684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of CD47 and Its Association With Tumor Immune Microenvironment Heterogeneity in Ovarian Cancer.
    Yu L; Ding Y; Wan T; Deng T; Huang H; Liu J
    Front Immunol; 2021; 12():768115. PubMed ID: 34966389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour immune cell infiltration and survival after platinum-based chemotherapy in high-grade serous ovarian cancer subtypes: A gene expression-based computational study.
    Liu R; Hu R; Zeng Y; Zhang W; Zhou HH
    EBioMedicine; 2020 Jan; 51():102602. PubMed ID: 31911269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crosstalk of RNA Adenosine Modification-Related Subtypes, Establishment of a Prognostic Model, and Immune Infiltration Characteristics in Ovarian Cancer.
    Ni X; Chen C; Cui G; Ding W; Liu J
    Front Immunol; 2022; 13():932876. PubMed ID: 35837397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated analysis of tumor-associated macrophage infiltration and prognosis in ovarian cancer.
    Tan Q; Liu H; Xu J; Mo Y; Dai F
    Aging (Albany NY); 2021 Oct; 13(19):23210-23232. PubMed ID: 34633990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune-Related Genes' Prognostic, Therapeutic and Diagnostic Value in Ovarian Cancer Immune-Related Gene Biomarker in Ovarian Cancer.
    Ding B; Yan W; Shen S; Meng D; Chen X; Wang S; Shen Y
    Cancer Control; 2023; 30():10732748231168756. PubMed ID: 37078136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving ovarian cancer treatment decision using a novel risk predictive tool.
    Xu Z; Song J; Cao L; Rong Z; Zhang W; He J; Li K; Hou Y
    Aging (Albany NY); 2022 Apr; 14(8):3464-3483. PubMed ID: 35439731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of the immune subtype of ovarian cancer patients by integrated analyses of transcriptome and single-cell sequencing data.
    Wang S; Wang X; Xia X; Zhang T; Yi M; Li Z; Jiang L; Yang Y; Fu J; Fang X
    Sci Rep; 2022 Aug; 12(1):13296. PubMed ID: 35918500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors.
    Pawłowska A; Rekowska A; Kuryło W; Pańczyszyn A; Kotarski J; Wertel I
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.